(Q52231710)

27 April 2018

review article

1 reference

title

Can we afford to treat hyperlipidaemia as we should? Strategies for rational treatment. (English)

1 reference

27 April 2018

1 reference

P N Durrington

1

1 reference

27 April 2018

publication date

1 September 1998

1 reference

27 April 2018

published in

Atherosclerosis

1 reference

27 April 2018

volume

139 Suppl 1

1 reference

27 April 2018

page(s)

S1-5

1 reference

27 April 2018

Assessing possible hazards of reducing serum cholesterol

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900187-7

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900187-7

Cholesterol reduction yields clinical benefit. A new look at old data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900187-7

Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900187-7

Lipid-lowering for prevention of coronary heart disease: what policy now?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900187-7

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900187-7

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900187-7

A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900187-7

Cholesterol screening guidelines consensus, evidence, and the departure from common sense

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900187-7

Awareness and control of hypertension and hypercholesterolaemia in France and Northern Ireland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900187-7

Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900187-7

Cardiovascular disease risk profiles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900187-7

Indications for cholesterol-lowering medication: comparison of risk-assessment methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900187-7

Screening for total cholesterol. Do the National Cholesterol Education Program's recommendations detect individuals at high risk of coronary heart disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900187-7

Mismatch of coronary risk and treatment intensity under the national cholesterol education program guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900187-7

10.1016/S0021-9150(98)00187-7

7 January 2021

Identifiers

DOI

1 reference

27 April 2018

1 reference

27 April 2018